美股新聞 標題聯播 · 近 24 小時 283 則 · 25 個來源 · 最新 9/20 07:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · IBRX近 30 天 14 則 · 第 1 / 1 頁
- ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
- ImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention?
- SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
- IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet
- PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
- SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck
- IBRX Stock Eyes Worst Week Since July: New Patent Eyes Broader Anktiva Use Ahead Of Lung Cancer Conference
- SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts
- Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
- SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
- IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update
- SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
- SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon
- SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology
- Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom
- SLS And IBRX Eye Green Weekly Close: Vanguard’s Major Stakes In Cancer Drugmakers Steal The Spotlight
- ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
- ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns
- The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses
- ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
- Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。